Become A Member!
Click on photo below for
Media Player audio of interview!
Steven S. Porter
Chairman and CEO
Interview conducted by:
Lynn Fosse, Senior Editor
July 20, 2006
This is a printer friendly page!
1444 Wazee Street, Suite 210
Denver, Colorado 80202
Steven S. Porter has served as Chief Executive Officer and Chairman since May 2005.
Prior to joining our company, he served as Chief Executive Officer and Chairman of the
Board of Osmotics from its inception in August 1993 until May 2005. He continues to serve
as a director of Osmotics Corporation. He has served as Chief Executive Officer and
Chairman of Osmotics Pharma since February 2002. In January 1986, Mr. Porter and two other
individuals founded GDP Technologies, Inc. (GDP), a medical imaging company, completing
major strategic partnerships with Olympus Optical, Japan, GE Medical and Bruel & Kjaer,
Denmark. From that time until August 1993, Mr. Porter served as Executive Vice President
of GDP. Prior to 1986, Mr. Porter was the National Sales Manager for Protronyx Research,
Inc., a large-scale scientific computer systems company, working with the United States
Department of Energy, United States Department of Defense, Boeing and the National
Security Agency. Mr. Porter has a Bachelor of Arts degree in Economics from UCLA.
Ceragenix Pharmaceuticals, Inc. (OTCBB: CGXP) is a biopharmaceutical company that
discovers, develops and commercializes novel anti-infective drugs based on its proprietary
class of compounds, Ceragenins(TM) (or CSAs). Active against a broad range of gram
positive and negative bacteria, these agents are being developed as anti-infective medical
device coatings (Ceracides(TM)) and as therapeutics for antibiotic-resistant organisms.
Ceragenix further owns exclusive rights to Barrier
Repair Technology for the treatment of dermatological disorders including atopic
dermatitis, neonatal skin disorders and others. Ceragenix's patented Barrier Repair
Technology, invented by Dr. Peter Elias and licensed from the University of California, is
the platform for the development of two prescription topical creams--EpiCeramŽ and
NeoCeramŽ. Ceragenix recently received 510K marketing clearance from the U.S. Food and
Drug Administration for its EpiCeramŽ Skin Barrier Emulsion to improve dry skin
conditions and to relieve and manage the burning and itching associated with various
dermatoses including atopic dermatitis, irritant contact dermatitis, radiation dermatitis,
and other dry skin conditions by maintaining a moist wound and skin environment.
Any reproduction or further distribution of this
article without the express written consent of CEOCFOinterviews.com is prohibited.